Turning uncertainty into evidence, value and access

AIM4ALL - Access to Innovative Medicines for All - sits at the intersection of health data, market-access strategy and innovative financing.

It provides a lower-risk orchestration layer through which health systems, pharmaceutical manufacturers and finance partners can collaborate. The model supports the generation of reliable real-world evidence, the development of innovative contracts and the pursuit of sustainable net pricing.

AIM4ALL does not replace clinical trials, health technology assessment or established reimbursement processes. It strengthens the evidence and operational infrastructure that connects them.

How we work

• Engage early - Health systems and pharmaceutical manufacturers begin working together earlier in the product lifecycle rather than waiting until launch.

• Define the evidence need - stakeholders agree on clinical datasets, patient populations, outcomes and HTA-relevant data elements.

• Prepare services and data infrastructure - care pathways and governance-compliant data-collection processes are standardised and digitalised.

• Generate longitudinal evidence - structured data can be collected from therapy-eligible patients before and after product launch.

• Support access decisions - pseudonymised insights support HTA, reimbursement, value-based agreements and sustainable pricing.